Abstract
The recent publication of the PEGASUS and COMPASS studies could have a great influence on the clinical management of patients with stable ischemic heart disease. In the presence of possible eligibility for both approaches, a practical tool based on inclusion/exclusion criteria of the two studies could be useful for clinical decision of ideal treatment for suitable patients. We therefore report a simple nomogram helpful in identifying the treatment indicated on the base of patient's characteristics.
MeSH terms
-
Aspirin / administration & dosage*
-
Cerebrovascular Disorders / drug therapy
-
Clinical Decision-Making
-
Clinical Protocols*
-
Drug Administration Schedule
-
Drug Therapy, Combination
-
Factor Xa Inhibitors / administration & dosage*
-
Humans
-
Myocardial Infarction / drug therapy
-
Myocardial Ischemia / drug therapy*
-
Peripheral Vascular Diseases / drug therapy
-
Platelet Aggregation Inhibitors / administration & dosage*
-
Randomized Controlled Trials as Topic
-
Registries
-
Risk
-
Rivaroxaban / administration & dosage*
-
Ticagrelor / administration & dosage*
Substances
-
Factor Xa Inhibitors
-
Platelet Aggregation Inhibitors
-
Rivaroxaban
-
Ticagrelor
-
Aspirin